CD274 and hepatocellular carcinoma: As mentioned above, immune checkpoint inhibitor (ICI) against PD-1/PD-L1 has been proven active, tolerable and clinically beneficial in advanced HCC patients and has been clinically applied as a first-line therapy worldwide.